360 MD Austin
Austin, TX
Physician credentials on file
§ — Substance profile
Bremelanotide · Vyleesi · Melanocortin receptor agonist
01 — Regulatory status
Regulatory status · United States · as of October 2026
FDA-approved (Vyleesi) for hypoactive sexual desire disorder in premenopausal women. Use in men or for other purposes is off-label.
Source: FDA 503A Bulks List · PCAC meeting records · verified October 2026
Reviewed October 2026 · Sources: FDA, EMA
02 — Researched for
Hypoactive sexual desire disorder in women; erectile dysfunction in men (earlier programs).
03 — What the evidence shows
Two phase 3 trials showed a modest increase in desire scores and a small reduction in distress versus placebo in the approved population.
04 — What is claimed but not shown
Reliable effect in men; benefit in postmenopausal women; performance enhancement.
05 — Known risks
Nausea in about 40% of users, flushing, transient blood pressure rise, focal hyperpigmentation with repeated use.
06 — Researched for these goals
Related substances
07 — Questions for your physician
Every practice in the registry that lists peptide therapy, sorted by distance and nothing else. You contact the practice directly.
Austin, TX
Physician credentials on file
La Jolla, CA
No physician listed on the practice website
Chandler, AZ
Physician credentials on file
Alpharetta, GA
Physician credentials on file
San Francisco, CA
Ahvie Herskowitz, MD · Ann Lee, MD
Steamboat Springs, CO
Physician credentials on file
Listed for transparency, not as an endorsement of any practice, substance or protocol. Most peptides are not FDA-approved for the uses they are offered for.
Reviewed October 2026 · Sources: FDA, EMA
This page reports on the state of research and regulation for orientation. It is not medical advice, not a recommendation for or against any substance, and not an offer. Regulatory status changes; the date shown is the date of our last verification. Discuss any treatment with a licensed physician.